Solamargine at low doses regulates the biological function of immune cells by inhibiting the LIF/Stat3 signaling pathway, reshaping the tumor microenvironment, and inhibiting the process of tumor cell heterogeneity, thereby exerting a synergistic antitumor effect. The gene discussed is LIF; the disease is neoplasm.